0001246360-15-001488.txt : 20150313
0001246360-15-001488.hdr.sgml : 20150313
20150313174908
ACCESSION NUMBER: 0001246360-15-001488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150311
FILED AS OF DATE: 20150313
DATE AS OF CHANGE: 20150313
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP
CENTRAL INDEX KEY: 0000911326
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 561808663
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: (781) 357-9900
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVE.
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: TRIMERIS INC
DATE OF NAME CHANGE: 19970516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heberlig Chris
CENTRAL INDEX KEY: 0001532217
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23155
FILM NUMBER: 15700525
MAIL ADDRESS:
STREET 1: 128 SPRING STREET, SUITE 520
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form.xml
PRIMARY DOCUMENT
X0306
4
2015-03-11
false
0000911326
SYNAGEVA BIOPHARMA CORP
GEVA
0001532217
Heberlig Chris
33 HAYDEN AVE
LEXINGTON
MA
02421
false
true
false
false
SVP, Finance and Business Ops.
Common Stock
2015-03-11
4
A
false
86
76.88
A
390
D
Common Stock
2015-03-11
4
M
false
7500
40.74
A
7890
D
Common Stock
2015-03-11
4
S
false
900
100.44
D
6990
D
Common Stock
2015-03-11
4
S
false
600
101.38
D
6390
D
Common Stock
2015-03-11
4
S
false
900
102.46
D
5490
D
Common Stock
2015-03-11
4
S
false
3290
103.55
D
2200
D
Common Stock
2015-03-11
4
S
false
1510
104.57
D
690
D
Common Stock
2015-03-11
4
S
false
300
105.74
D
390
D
Stock Option (Right to Buy)
40.74
2015-03-11
4
M
false
7500
0
D
2022-06-27
Common Stock
7500
7500
D
The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c).
The reporting person is voluntarily reporting this transaction as of 03/11/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP.
In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period.
The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 3, 2014.
The Stock Option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 06/27/2013, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.10 to $100.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.12 to $101.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.98 to $102.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $103.00 to $103.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $104.15 to $105.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $105.59 to $106.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
/s/ Chris Heberlig
2015-03-13